Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical -propeller domain
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical -propeller domain
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 111, Issue 14, Pages 5195-5200
Publisher
Proceedings of the National Academy of Sciences
Online
2014-03-25
DOI
10.1073/pnas.1322892111
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
- (2013) Jim Sang et al. Cancer Discovery
- Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
- (2012) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
- (2012) L. Neckers et al. CLINICAL CANCER RESEARCH
- EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
- (2012) Erik Thunnissen et al. VIRCHOWS ARCHIV
- Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer
- (2011) K. Takezawa et al. CLINICAL CANCER RESEARCH
- Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
- (2011) W. Ying et al. MOLECULAR CANCER THERAPEUTICS
- The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
- (2011) E Normant et al. ONCOGENE
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
- (2010) Z. Chen et al. CANCER RESEARCH
- The biology and treatment of EML4-ALK non-small cell lung cancer
- (2010) Takaaki Sasaki et al. EUROPEAN JOURNAL OF CANCER
- Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
- (2010) Xuchao Zhang et al. Molecular Cancer
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- MolProbity: all-atom structure validation for macromolecular crystallography
- (2009) Vincent B. Chen et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Intrinsic Structural Disorder Confers Cellular Viability on Oncogenic Fusion Proteins
- (2009) Hedi Hegyi et al. PLoS Computational Biology
- The C. elegans EMAP-like protein, ELP-1 is required for touch sensation and associates with microtubules and adhesion complexes
- (2008) Jennifer L Hueston et al. BMC DEVELOPMENTAL BIOLOGY
- Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer
- (2008) Y. L. Choi et al. CANCER RESEARCH
- EML3 is a nuclear microtubule-binding protein required for the correct alignment of chromosomes in metaphase
- (2008) J. Tegha-Dunghu et al. JOURNAL OF CELL SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started